 Xiu-Ti Hu
Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cocaine | 13 | 2015 | 43 | 4.060 |
Why?
| | Nucleus Accumbens | 10 | 2014 | 25 | 3.430 |
Why?
| | Calcium Channels, L-Type | 6 | 2016 | 56 | 2.870 |
Why?
| | Pyramidal Cells | 10 | 2016 | 31 | 2.700 |
Why?
| | Neurons | 11 | 2017 | 365 | 2.660 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 5 | 2016 | 16 | 2.430 |
Why?
| | Prefrontal Cortex | 11 | 2016 | 124 | 2.270 |
Why?
| | Action Potentials | 8 | 2015 | 94 | 1.710 |
Why?
| | Dopamine Uptake Inhibitors | 6 | 2011 | 16 | 1.620 |
Why?
| | HIV-1 | 6 | 2017 | 402 | 1.600 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 2 | 2016 | 34 | 1.530 |
Why?
| | Rats, Sprague-Dawley | 17 | 2015 | 474 | 1.130 |
Why?
| | Rats | 19 | 2017 | 947 | 1.110 |
Why?
| | Neuronal Plasticity | 4 | 2009 | 41 | 1.000 |
Why?
| | AIDS Dementia Complex | 3 | 2017 | 34 | 0.990 |
Why?
| | Animals | 24 | 2017 | 4673 | 0.950 |
Why?
| | Substance Withdrawal Syndrome | 3 | 2010 | 32 | 0.930 |
Why?
| | Sodium Channels | 3 | 2006 | 15 | 0.830 |
Why?
| | Patch-Clamp Techniques | 10 | 2016 | 134 | 0.820 |
Why?
| | Membrane Potentials | 8 | 2016 | 211 | 0.820 |
Why?
| | Receptors, Dopamine D2 | 2 | 2006 | 14 | 0.760 |
Why?
| | Potassium Channels | 2 | 2006 | 42 | 0.750 |
Why?
| | Cerebral Cortex | 2 | 2014 | 171 | 0.730 |
Why?
| | Substance-Related Disorders | 3 | 2017 | 99 | 0.690 |
Why?
| | Calcium | 5 | 2011 | 466 | 0.640 |
Why?
| | Calcium Channels | 4 | 2011 | 130 | 0.640 |
Why?
| | Homeostasis | 2 | 2011 | 96 | 0.630 |
Why?
| | Central Nervous System Stimulants | 3 | 2017 | 54 | 0.620 |
Why?
| | Excitatory Postsynaptic Potentials | 3 | 2011 | 11 | 0.580 |
Why?
| | In Vitro Techniques | 7 | 2011 | 253 | 0.560 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 6 | 2011 | 34 | 0.540 |
Why?
| | Signal Transduction | 6 | 2017 | 506 | 0.510 |
Why?
| | Calcineurin | 2 | 2011 | 12 | 0.510 |
Why?
| | Male | 21 | 2017 | 14071 | 0.510 |
Why?
| | Methamphetamine | 3 | 2017 | 44 | 0.500 |
Why?
| | Oncogene Proteins v-fos | 1 | 2008 | 2 | 0.470 |
Why?
| | Receptors, Dopamine D1 | 3 | 2011 | 7 | 0.470 |
Why?
| | Calcium Signaling | 2 | 2016 | 162 | 0.460 |
Why?
| | Dopamine Agonists | 5 | 2011 | 43 | 0.450 |
Why?
| | Inhibitory Postsynaptic Potentials | 1 | 2006 | 2 | 0.410 |
Why?
| | Cyclic AMP | 3 | 2005 | 34 | 0.400 |
Why?
| | Enzyme Inhibitors | 6 | 2011 | 151 | 0.390 |
Why?
| | Electric Stimulation | 5 | 2011 | 89 | 0.390 |
Why?
| | Phosphoproteins | 1 | 2005 | 33 | 0.370 |
Why?
| | Muscarine | 1 | 2004 | 2 | 0.360 |
Why?
| | Ion Channels | 1 | 2007 | 233 | 0.340 |
Why?
| | beta Catenin | 2 | 2017 | 47 | 0.340 |
Why?
| | Nerve Tissue Proteins | 1 | 2005 | 145 | 0.330 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2011 | 498 | 0.320 |
Why?
| | Ventral Tegmental Area | 1 | 2002 | 11 | 0.310 |
Why?
| | Amphetamine | 1 | 2002 | 15 | 0.310 |
Why?
| | Organ Culture Techniques | 2 | 2014 | 38 | 0.290 |
Why?
| | Self Administration | 3 | 2015 | 32 | 0.270 |
Why?
| | Dopamine Antagonists | 3 | 2011 | 13 | 0.250 |
Why?
| | Drug Interactions | 3 | 2011 | 67 | 0.250 |
Why?
| | Dopamine | 3 | 2007 | 159 | 0.240 |
Why?
| | Analysis of Variance | 2 | 2011 | 352 | 0.240 |
Why?
| | Time Factors | 5 | 2011 | 1581 | 0.230 |
Why?
| | Salicylamides | 2 | 2011 | 2 | 0.230 |
Why?
| | Quinpirole | 2 | 2011 | 3 | 0.230 |
Why?
| | Astrocytes | 2 | 2017 | 105 | 0.220 |
Why?
| | Drug Administration Schedule | 3 | 2011 | 248 | 0.220 |
Why?
| | HIV Infections | 2 | 2016 | 761 | 0.210 |
Why?
| | Electrophysiological Phenomena | 1 | 2016 | 11 | 0.190 |
Why?
| | Mice, Transgenic | 1 | 2016 | 236 | 0.190 |
Why?
| | Drug-Seeking Behavior | 1 | 2015 | 5 | 0.180 |
Why?
| | Serotonin 5-HT2 Receptor Agonists | 1 | 2014 | 2 | 0.180 |
Why?
| | Drug Inverse Agonism | 1 | 2014 | 3 | 0.180 |
Why?
| | Receptor, Serotonin, 5-HT2C | 1 | 2014 | 3 | 0.180 |
Why?
| | Cues | 1 | 2015 | 74 | 0.170 |
Why?
| | Gene Expression Regulation | 3 | 2017 | 317 | 0.170 |
Why?
| | Potassium Channel Blockers | 3 | 2009 | 8 | 0.160 |
Why?
| | Motor Cortex | 2 | 2009 | 13 | 0.150 |
Why?
| | Biophysics | 2 | 2009 | 47 | 0.150 |
Why?
| | Street Drugs | 1 | 2011 | 9 | 0.140 |
Why?
| | Nitric Oxide Synthase Type I | 1 | 2010 | 9 | 0.140 |
Why?
| | Reward | 2 | 2010 | 24 | 0.140 |
Why?
| | Disease Models, Animal | 2 | 2017 | 663 | 0.130 |
Why?
| | Sodium Channel Blockers | 2 | 2006 | 3 | 0.120 |
Why?
| | Cross-Linking Reagents | 1 | 2009 | 15 | 0.120 |
Why?
| | Protein Transport | 1 | 2009 | 41 | 0.120 |
Why?
| | 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 1 | 2008 | 2 | 0.120 |
Why?
| | Synapses | 1 | 2009 | 43 | 0.120 |
Why?
| | Mice, Mutant Strains | 1 | 2008 | 28 | 0.120 |
Why?
| | Mice | 2 | 2017 | 1588 | 0.120 |
Why?
| | Potassium Channels, Voltage-Gated | 2 | 2005 | 12 | 0.110 |
Why?
| | Calcium Channel Blockers | 2 | 2005 | 37 | 0.110 |
Why?
| | Humans | 5 | 2017 | 24300 | 0.110 |
Why?
| | Phosphorylation | 2 | 2005 | 191 | 0.110 |
Why?
| | Receptors, Dopamine | 1 | 2007 | 31 | 0.100 |
Why?
| | Brain | 1 | 2016 | 1136 | 0.100 |
Why?
| | Type C Phospholipases | 1 | 2006 | 11 | 0.100 |
Why?
| | Adaptation, Physiological | 1 | 2007 | 60 | 0.100 |
Why?
| | Synaptic Transmission | 1 | 2006 | 45 | 0.100 |
Why?
| | Dopamine and cAMP-Regulated Phosphoprotein 32 | 1 | 2005 | 2 | 0.090 |
Why?
| | Protein Phosphatase 1 | 1 | 2005 | 4 | 0.090 |
Why?
| | Motor Activity | 1 | 2009 | 358 | 0.090 |
Why?
| | Muscarinic Antagonists | 1 | 2004 | 1 | 0.090 |
Why?
| | Parasympathomimetics | 1 | 2004 | 3 | 0.090 |
Why?
| | Pertussis Toxin | 1 | 2004 | 4 | 0.090 |
Why?
| | Atropine | 1 | 2004 | 4 | 0.090 |
Why?
| | Thionucleotides | 1 | 2004 | 6 | 0.090 |
Why?
| | Egtazic Acid | 1 | 2004 | 13 | 0.090 |
Why?
| | Chelating Agents | 1 | 2004 | 11 | 0.090 |
Why?
| | Models, Neurological | 1 | 2004 | 29 | 0.090 |
Why?
| | Blotting, Western | 1 | 2005 | 225 | 0.090 |
Why?
| | Ion Channel Gating | 1 | 2006 | 193 | 0.090 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2004 | 4 | 0.090 |
Why?
| | Genes, Immediate-Early | 1 | 2002 | 2 | 0.080 |
Why?
| | Microinjections | 1 | 2002 | 6 | 0.080 |
Why?
| | Animals, Genetically Modified | 1 | 2017 | 15 | 0.050 |
Why?
| | Primary Cell Culture | 1 | 2017 | 16 | 0.050 |
Why?
| | Excitatory Amino Acid Antagonists | 2 | 2009 | 16 | 0.050 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2017 | 24 | 0.050 |
Why?
| | Rats, Transgenic | 1 | 2015 | 15 | 0.050 |
Why?
| | Rats, Inbred F344 | 1 | 2015 | 47 | 0.050 |
Why?
| | Conditioning, Operant | 1 | 2015 | 15 | 0.050 |
Why?
| | DNA-Binding Proteins | 1 | 2017 | 182 | 0.050 |
Why?
| | Indazoles | 1 | 2010 | 3 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2012 | 463 | 0.030 |
Why?
| | Female | 1 | 2008 | 14317 | 0.030 |
Why?
| | Cocaine-Related Disorders | 1 | 2010 | 16 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 218 | 0.030 |
Why?
| | Down-Regulation | 1 | 2011 | 131 | 0.030 |
Why?
| | Cell Line | 1 | 2011 | 334 | 0.030 |
Why?
| | Behavior, Animal | 1 | 2010 | 103 | 0.030 |
Why?
| | Up-Regulation | 1 | 2011 | 184 | 0.030 |
Why?
| | Small-Conductance Calcium-Activated Potassium Channels | 1 | 2009 | 1 | 0.030 |
Why?
| | Apamin | 1 | 2009 | 2 | 0.030 |
Why?
| | Tissue Culture Techniques | 1 | 2009 | 13 | 0.030 |
Why?
| | Macrolides | 1 | 2009 | 8 | 0.030 |
Why?
| | Transduction, Genetic | 1 | 2009 | 21 | 0.030 |
Why?
| | Green Fluorescent Proteins | 1 | 2009 | 41 | 0.030 |
Why?
| | Comorbidity | 1 | 2011 | 458 | 0.030 |
Why?
| | RNA Interference | 1 | 2009 | 41 | 0.030 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2009 | 37 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2009 | 65 | 0.030 |
Why?
| | Peptides | 1 | 2009 | 105 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2009 | 180 | 0.030 |
Why?
| | Kynurenic Acid | 1 | 2005 | 1 | 0.020 |
Why?
| | Cadmium Chloride | 1 | 2005 | 1 | 0.020 |
Why?
| | Tetraethylammonium | 1 | 2005 | 4 | 0.020 |
Why?
| | GABA Antagonists | 1 | 2005 | 3 | 0.020 |
Why?
| | Tetrodotoxin | 1 | 2005 | 8 | 0.020 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2005 | 19 | 0.020 |
Why?
| | Cesium | 1 | 2005 | 14 | 0.020 |
Why?
| | Nifedipine | 1 | 2005 | 8 | 0.020 |
Why?
| | Chlorides | 1 | 2005 | 28 | 0.020 |
Why?
| | Barium | 1 | 2004 | 12 | 0.020 |
Why?
| | Evoked Potentials | 1 | 2004 | 17 | 0.020 |
Why?
| | Cell Separation | 1 | 2004 | 44 | 0.020 |
Why?
|
|
Hu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|